Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing.

Yukl SA, Kaiser P, Kim P, Telwatte S, Joshi SK, Vu M, Lampiris H, Wong JK.

Sci Transl Med. 2018 Feb 28;10(430). pii: eaap9927. doi: 10.1126/scitranslmed.aap9927.

2.

Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.

Li P, Kaiser P, Lampiris HW, Kim P, Yukl SA, Havlir DV, Greene WC, Wong JK.

Nat Med. 2016 Jul;22(7):807-11. doi: 10.1038/nm.4124. Epub 2016 Jun 13.

3.

Neuraminidase Inhibitors and Influenza Infection-Reply.

Louie JK, Lampiris H.

JAMA Intern Med. 2016 Mar;176(3):416-7. doi: 10.1001/jamainternmed.2016.0050. No abstract available.

PMID:
26954054
4.

Treating Influenza With Neuraminidase Inhibitors: What Is the Evidence?

Louie JK, Lampiris H.

JAMA Intern Med. 2015 Dec;175(12):1899-900. doi: 10.1001/jamainternmed.2015.5747. Review. No abstract available.

PMID:
26501509
5.

Geriatric Syndromes in Older HIV-Infected Adults.

Greene M, Covinsky KE, Valcour V, Miao Y, Madamba J, Lampiris H, Cenzer IS, Martin J, Deeks SG.

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):161-7. doi: 10.1097/QAI.0000000000000556.

6.

The Montreal Cognitive Assessment: A Pilot Study of a Brief Screening Tool for Mild and Moderate Cognitive Impairment in HIV-Positive Veterans.

Chartier M, Crouch PC, Tullis V, Catella S, Frawley E, Filanosky C, Carmody T, McQuaid J, Lampiris H, Wong JK.

J Int Assoc Provid AIDS Care. 2015 May-Jun;14(3):197-201. doi: 10.1177/2325957414557270. Epub 2014 Dec 8.

PMID:
25487428
7.

Management of human immunodeficiency virus infection in advanced age.

Greene M, Justice AC, Lampiris HW, Valcour V.

JAMA. 2013 Apr 3;309(13):1397-405. doi: 10.1001/jama.2013.2963. Review.

8.

Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.

Lampiris HW.

Expert Rev Anti Infect Ther. 2012 Jan;10(1):13-20. doi: 10.1586/eri.11.157. Review.

PMID:
22149610
9.

Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.

Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T, Pandori M, Havlir DV, Wong JK.

J Virol Methods. 2011 Aug;175(2):261-5. doi: 10.1016/j.jviromet.2011.04.015. Epub 2011 Apr 22.

10.

A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG.

J Infect Dis. 2011 Apr 1;203(7):960-8. doi: 10.1093/infdis/jiq138.

11.

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G Jr, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC Jr, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL Jr, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC 3rd, Olender SA, Ostrowski M, Owen WF Jr, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM Jr, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Telenti A, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M.

Science. 2010 Dec 10;330(6010):1551-7. doi: 10.1126/science.1195271. Epub 2010 Nov 4.

12.

Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.

Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi AL, Girling V, Ho T, Li P, Fujimoto K, Lampiris H, Hare CB, Pandori M, Haase AT, Günthard HF, Fischer M, Shergill AK, McQuaid K, Havlir DV, Wong JK.

J Infect Dis. 2010 Nov 15;202(10):1553-61. doi: 10.1086/656722. Epub 2010 Oct 12.

13.

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, Pandori M, Sinclair E, Günthard HF, Fischer M, Wong JK, Havlir DV.

AIDS. 2010 Oct 23;24(16):2451-60. doi: 10.1097/QAD.0b013e32833ef7bb.

14.

Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.

Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R, Martin JN, Lalezari J, Bangsberg D, Petropoulos C, Deeks SG.

J Acquir Immune Defic Syndr. 2010 Aug;54(4):389-93. doi: 10.1097/QAI.0b013e3181c42ea4.

15.

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.

Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, Kearney BP, Cheng AK.

J Infect Dis. 2010 Mar 15;201(6):814-22. doi: 10.1086/650698.

PMID:
20146631
16.

Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy.

Cardenas VA, Meyerhoff DJ, Studholme C, Kornak J, Rothlind J, Lampiris H, Neuhaus J, Grant RM, Chao LL, Truran D, Weiner MW.

J Neurovirol. 2009 Jul;15(4):324-33. doi: 10.1080/13550280902973960.

17.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

18.

Resolution of hepatitis C virus-induced steatosis improves tolerability of antiretroviral drugs associated with hepatotoxicity in an HIV-infected individual.

Shah T, Lampiris H, Vu M, Monto A, Tien PC.

J Infect Dis. 2008 Mar 15;197(6):932-3. doi: 10.1086/528800. No abstract available.

PMID:
18419352
19.

Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG.

J Infect Dis. 2008 Jan 1;197(1):126-33. doi: 10.1086/524143.

20.

Covering all the bases: targeting HIV-1 integrase.

Wong JK, Lampiris H.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):507-8. No abstract available.

PMID:
17133210
21.

Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.

Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG.

J Infect Dis. 2006 Oct 1;194(7):926-30. Epub 2006 Aug 29.

PMID:
16960780
22.

The independent effect of drug resistance on T cell activation in HIV infection.

Hunt PW, Deeks SG, Bangsberg DR, Moss A, Sinclair E, Liegler T, Bates M, Tsao G, Lampiris H, Hoh R, Martin JN.

AIDS. 2006 Mar 21;20(5):691-9.

PMID:
16514299
23.

T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG.

J Infect Dis. 2003 May 15;187(10):1534-43. Epub 2003 Apr 23.

PMID:
12721933
24.

Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.

Hare CB, Vu MP, Grunfeld C, Lampiris HW.

Clin Infect Dis. 2002 Nov 15;35(10):e111-2. Epub 2002 Oct 25.

PMID:
12410494
25.

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.

Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E, Cheng AK; Study 902 Team.

AIDS. 2002 Jun 14;16(9):1257-63.

PMID:
12045491
26.

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.

Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B.

Clin Infect Dis. 2002 Jun 1;34(11):1481-90. Epub 2002 May 13.

PMID:
12015695
27.

Streptococcus pneumoniae transmission in chronic-care facilities: description of an outbreak and review of management strategies.

Sheppard DC, Bartlett KA, Lampiris HW.

Infect Control Hosp Epidemiol. 1998 Nov;19(11):851-3.

PMID:
9831942

Supplemental Content

Loading ...
Support Center